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Background: Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. influenzae) are considered
major causes of bacterial acute otitis media (AOM) worldwide, but data from Asia on primary causes of AOM are
limited. This tympanocentesis-based, multi-center, cross-sectional study assessed bacterial etiology and antimicrobial
susceptibility of AOM in Thailand.
Methods: Children 3 to 59 months presenting with AOM (< 72 hours of onset) who had not received prescribed
antibiotics, or subjects who received prescribed antibiotics but remained symptomatic after 48–72 hours (treatment
failures), were eligible. Study visits were conducted from April 2008 to August 2009. Bacteria were identified
from middle ear fluid collected by tympanocentesis or spontaneous otorrhea swab sampling (< 20% of cases).
S. pneumoniae and H. influenzae serotypes were determined and antimicrobial resistance was also assessed.
Results: Of the 123 enrolled children, 112 were included in analysis and 48% of the 118 samples were positive for
S. pneumoniae (23% (27/118)), H. influenzae (18% (21/118)), Moraxella catarrhalis (6% (7/118)) or Streptococcus
pyogenes (3% (4/118)). The most common pneumococcal serotypes were 19F (26%) and 14 (22%). The majority of
H. influenzae isolates were encapsulated (18/21), with 13 type b (Hib) representing 62% of all H. influenzae isolate or
11% of all samples (13/118), and there were only 3 non-typeable isolates. Despite high antibiotic resistance,
amoxicillin/clavulanate susceptibility was high. No pneumococcal vaccine use was reported.
Conclusions: S. pneumoniae and H. influenzae, both frequently antibiotic resistant, were leading causes of bacterial
AOM and there was an unexpectedly high burden of Hib in this population unvaccinated by any Hib conjugate
vaccine. Conjugate vaccines effective against pneumococcus and H. influenzae could potentially reduce the burden
of AOM in this population.
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Acute otitis media (AOM) is one of the most frequent
bacterial infections in children, and one of the primary
reasons for the prescription of antibiotics by pediatricians
[1,2]. Streptococcus pneumoniae (S. pneumoniae) and non-
typeable Haemophilus influenzae (H. influenzae) have his-
torically been considered the leading causes of bacterial
AOM [3]. Following introduction of the 7-valent pneumo-
coccal conjugate vaccine (PCV7), in the United States, a
relative increase in non-PCV7 serotypes and non-typeable
H. influenzae (NTHi) was observed. There were few cases
of AOM due to Moraxella catarrhalis (M. catarrhalis) or
Streptococcus pyogenes (S. pyogenes) and no reported cases
due to H. influenzae type b (Hib) [4]. Even prior to the
Hib vaccination era, encapsulated H. influenzae was rarely
reported as a cause of AOM in the United States [3].
Most data on the topic come from North America and
Europe, however, and studies of the burden, etiology and
societal impact of AOM in Asia are sparse. While some
studies suggest a low estimated prevalence [5,6] and a
lower physician-reported frequency of AOM visits in Asia
than elsewhere [7], others have highlighted the import-
ance of AOM in the region [6]. The significant regional
burden of chronic suppurative otitis media [8], a compli-
cation of AOM, suggests that AOM is indeed of public
health concern.
Regional treatment patterns of AOM may also raise
concerns given the extremely high rates of penicillin non-
susceptibility of S. pneumoniae isolates and of ampicillin/
amoxicillin resistance for H. influenzae non-invasive iso-
lates documented in young children in East Asia [9-11]. A
recent survey reported that most of the physicians in
Asian countries use oral antibiotics as part of first line
treatment of AOM [7], despite ‘watchful waiting’ recom-
mendations in many countries across the world [12,13].
There is thus a need for AOM etiology data in the re-
gion, ideally from tympanocentesis samples, as data extrap-
olated from pathogen distribution from nasopharyngeal
samples do not necessarily represent pathogen distribution
in the middle ear [14,15]. This study aimed to add to the
limited AOM data in Thailand, to characterize the bacter-
ial etiology and serotypes of AOM cases in young children
in Thailand, where both Hib and pneumococcal conjugate
vaccine use are reported to be only <5% [16,17], and to de-
termine antibiotic susceptibility of the pathogens. These
data could have important clinical implications for deter-
mining the best approach for prevention and treatment of
AOM in Thailand [18,19].
Methods
Study design
This was a tympanocentesis-based, multi-center, cross-
sectional study conducted within a routine clinical set-
ting in several regions of Thailand: 2 centers in Bangkok,one in Hatyai in southern Thailand and one in Chiang
Mai in northern Thailand. Target enrollment was at least
100 patients over a year, based on the assumption that
in the context of high antibiotic use, 40% of samples
would be culture positive [3,4,20]. The study included
children 3 to 59 months of age visiting Ear Nose and
Throat (ENT) clinics for AOM, and from whom a mid-
dle ear fluid (MEF) sample was available either by tympa-
nocentesis or careful sampling of spontaneous otorrhea
which occurred less than 24 hours prior to the visit.
Eligible patients were either subjects with a new epi-
sode of AOM (less than 72 hours since onset of
symptoms) who had not yet received any antibiotics
prescribed by a physician, or subjects who were diag-
nosed with AOM within 48–72 hours prior to study
enrollment, received antibiotic therapy from a phys-
ician, but remained symptomatic at the time of study
entry (treatment failures). Patients who received sys-
temic antibiotic treatment for a disease other than AOM
in the 72 hours prior to enrollment, and patients receiving
antimicrobial prophylaxis for recurrent AOM, defined as
at least 3 episodes in the past 6 months or 4 episodes in
the past 12 months, were excluded. Children who were
hospitalized during the diagnosis or treatment of AOM
were also excluded. All study visits took place between 2
April 2008 and 28 August 2009.
During screening and enrollment, ENTs maintained a
logbook to collect anonymized demographic information
for subjects 3 to 59 months of age who were diagnosed
with AOM to determine the representativeness of the
AOM patients who were included in the study. ENTs
obtained informed consent from parents/guardians of
eligible children prior to performance of any study-
specific procedures. Once enrolled, demographics, med-
ical history, care history and general symptoms were
collected and a clinical examination was performed;
AOM was diagnosed after otoscopic examination of the
tympanic membrane by the ENT and was classified ac-
cording to the otoscopy score (8 grades) (OS-8), which
measures the severity of tympanic-membrane inflamma-
tion. The OS-8 scale is only appropriate for use in chil-
dren with an intact tympanic membrane, and therefore
was not used for children with otorrhea. Spontaneous
otorrhea or an OS-8 score of at least 2 was necessary
for the child to meet AOM diagnosis criteria. The
levels of the OS-8 scale from level 2 are as follows: 2
indicates hyperemia, air-fluid level, no opacification,
meniscus noted; 3 indicates hyperemia, complete effu-
sion, no opacification; 4 indicates hyperemia, opacifi-
cation, air-fluid level observed, no bulging; 5 indicates
hyperemia, complete effusion, opacification, and no bul-
ging; 6 indicates hyperemia, bulging rounded doughnut
appearance of tympanic membrane; 7 indicates hyperemia
with bulla formation.
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MEF samples were collected by performing tympanocent-
esis. In cases of otorrhea, investigators were advised to re-
move and clean the ear canal material, and deep aspiration
of the MEF material, via needle insertion, was attempted to
avoid contamination and spurious results. Since pathogen
distribution from tympanocentesis and otorrhea may differ
[21], the study protocol limited otorrhea samples to repre-
sent no more than 20% of all subjects.
Samples were kept in Amies transport media and
transferred to the central laboratory within 16 hours for
plating at room temperature. Analysis of samples was
performed at a central laboratory to isolate bacterial
pathogens, assess serotypes and determine the anti-
microbial susceptibility profile. MEF samples were inoc-
ulated in chocolate agar and blood agar with gentamycin
and otorrhea samples were inoculated in chocolate agar
with bacitracin and blood agar with gentamycin. S. pneu-
moniae serotyping was performed through polymerase
chain reaction (PCR) [22] and H. influenzae serotyping
was performed through monovalent antisera a, b, c, d, e
and f at the International Emerging Infections Program
of the United States Centers for Disease Control and
Prevention. After initial serotyping of H. influenzae iso-
lates the results were confirmed by a second laboratory
which was blinded to the initial serotyping results. Defi-
nitions of antimicrobial susceptibility were based on the
Clinical and Laboratory Standards Institute 2009 stan-
dards [23]. Susceptibility to the following antibiotics was
assessed: penicillin, amoxicillin/clavulanate, cefuroxime,
cefotaxime, erythromycin, azithromycin, ampicillin, chlor-
amphenicol, tetracycline, levofloxacin and trimethoprim/
sulfamethoxazole.
Statistical analysis
Children with bilateral infections were considered a single
episode but had 2 samples collected, one from each ear.
Descriptive statistics were used to compare demographics,
clinical characteristics, pathogen distribution and anti-
biotic susceptibility among enrolled children. All statistical
analyses were performed using SAS, version 9.1 or later
(SAS Institute Inc., Cary, NC, USA), and Microsoft Excel
(2002 SP3 or later), for graphical purposes.
Ethical approval
The study protocol was reviewed by the ethical review
committees of all participating hospitals and the Ethical
Review Committee for Research in Human Subjects at
the Thailand Ministry of Public Health.
Results
Study subjects
Study visits took place for 123 children experiencing AOM
among 263 screened children (Figure 1). One hundred andtwelve children fulfilled study criteria. Nine of the 112 (8%)
children were classified as treatment failures. Six of the
112 children were experiencing bilateral infections for
which samples from both the left and right ears were col-
lected. Of the 118 samples collected, 91% (107/118) were
collected by tympanocentesis. The primary reason for non-
enrollment was spontaneous otorrhea more than 24 hours
prior to the visit (n = 52).
Demographic characteristics and clinical history
The median age of screened children was 33.5 months
compared to a median age of 36 months among partici-
pating children (range 5–59 months) (Table 1). Nine per-
cent (10/112) of participating children were between 3
and 11 months of age, 14% (16/112) were between 12 and
23 months, and the remainders were uniformly distributed
between the other classes of age (24–35, 36–47 and 48–59
months). Fifty-five percent (62/112) of participating chil-
dren were females. Sixty-four percent (7/11) of children
with spontaneous otorrhea were less than 24 months of
age, while 19% (19/101) of children in whom tympano-
centesis was used were less than 24 months. None of the
children had received any doses of a pneumococcal conju-
gate vaccine, while 4% (5/112) had received at least one
dose of influenza vaccine. Antibiotic use within the past
month was reported for 23% (26/112) of children. AOM
was classified as recurrent for 7% (8/112) of children.
Microbiology
Overall, 48% (57/118) of samples yielded cultures with
one of the 4 bacterial pathogens under study (S. pneu-
moniae, H. influenzae, M. catarrhalis or S. pyogenes)
(Figure 2), 2 of which were positive for more than one
bacteria. The most frequently detected bacteria was S.
pneumoniae (47% (27/57)), followed by H. influenzae (37%
(21/57)), M. catarrhalis (12% (7/57)) and S. pyogenes (7%
(4/57)). Among the 11 samples collected from otorrhea
episodes, one was positive for S. pneumoniae, 2 for H.
influenzae and 3 for S. pyogenes. Two of the 9 treatment
failure samples were positive for a pathogen under study,
both of which were S. pneumoniae. The most common
pneumococcal serotypes isolated from the 27 S. pneumo-
niae-isolates were 19F (7/27 (26%)), 14 (6/27 (22%)) and 3
(4/27 (15%)) (Figure 2). Out of the 21H. influenzae iso-
lates, 13 (62%) were serotype b (Hib), 3 (14%) were non-
typeable, and the remainders were serotypes a (1 isolate
(5%)), d (2 isolates (10%)) and f (1 isolate (5%)), with one
(5%) missing (Figure 2). Overall, Hib was detected in
11% of all samples (13/118). The 2 co-infected samples
were due to one co-infection of S. pneumoniae 23F and
H. influenzae serotype a, and one co-infection of Hib and
M. catarrhalis.
S. pneumoniae and Hib and non-Hib H. influenzae
were the most commonly detected pathogens in all age
263 children screened
123 children enrolled
112 children included in cohort
-103 untreated
-9 treatment failures 
11 children excluded*
-5 received systemic anbiocs in past 
72 hours for disease other than AOM
-3 onset of AOM >72 hours prior to  
diagnosis
-5 did not meet criteria for AOM 
-1 hospitalized during AOM
-1 provided anbiocs by ENT prior to 
tympanocentesis
118 samples**          
-107 collected by tympanocentesis
-11 collected by otorrhea




- 4 S. pyogenes
-7 M. catarrhalis
61 samples – cultures yielded no  
study pathogen 
140 children not enrolled
-52 spontaneous otorrhea > 24 hours
-34 no indicaon for tympanocentesis
-17 exceeded 20% otorrhea guideline
-11 parent refused enrollment
-26 not enrolled for other reasons
Figure 1 Enrollment and etiology of AOM patients included in the study.
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months, S. pneumoniae and H. influenzae were each iso-
lated from 2/10 episodes (20%). Among children 12–35
months of age, S. pneumoniae was isolated from 7/45
(15.5%) episodes while H. influenzae was detected in
10/45 (22%). In the oldest children, 36–59 months of
age, S. pneumoniae was detected from 17/57 (30%)
episodes, and H. influenzae from 9/57 (16%). Potential
risk and protective factors, including premature birth,
HIV infection, child care attended, child breast-fed and
number of household siblings less than 5, were similar
when compared by pathogen (data not shown). Due to
small numbers, the differences in age group and potential
risk factors by pathogen were not tested for statistical
significance.
Symptoms
The most frequently reported symptom was ear pain,
reported for 95% (106/112) of episodes, followed by irrit-
ability, reported for 49% (55/112) of episodes (Table 2).
Fever was reported for 12% (3/26) of children experiencingAOM due to S. pneumoniae but was not reported for
any children experiencing AOM due to Hib or non-Hib
H. influenzae. Trouble sleeping was reported for 2% (2/26)
of children experiencing AOM due to S. pneumoniae, 31%
(4/13) of those experiencing AOM due to Hib and 25%
(2/8) of those experiencing AOM due to non-Hib H.
influenzae (Table 2). Due to small numbers, the differ-
ences in symptoms by pathogen were not tested for statis-
tical significance.
Hib-positive AOM
Thirty-eight percent (5/13) of Hib-positive AOM and
13% (1/8) of AOM due to other H. influenzae were in
children 12–23 months, compared to 14% (16/112) of
AOM overall. Fifteen percent (2/13) of children with
Hib-positive AOM and 13% (1/8) of children with AOM
due to other H. influenzae reported taking antibiotics in
the past month. Two of the 3 children who experienced
hearing loss had Hib-positive AOM. Irritability and ear
tugging were reported for a greater proportion of chil-
dren with Hib-positive AOM compared to children with







Hib M. catarrhalis S. pyogenes
Age
3–11 months 10 5 (50%) 2 1 1 0 1
12–23 months 16 10 (63%)1 2 1 51 11 2
24–35 months 29 11 (38%) 5 2 2 2 0
36–47 months 28 14 (50%) 82 0 4 2 0
48–59 months 29 16 (55%)3 93 43 1 2 1
Total episodes 112 56 (51%)1,3 262,3 (23%) 8 (7%)3 13 (12%)1 7 (6%)1 4 (4%)
Male 51 26 (51%) 102 (20%) 5 (10%) 7 (14%) 1 (2%) 3 (6%)
Collection method
Otorrhea 11 6 (55%) 1 1 1 0 3
Tympanocentesis 107 51 (48%) 264 7 12 7 1
Total samples 1184 57 (48%) 27 (23%)4 8 (7%) 13 (11%) 7 (6%) 4 (3%)
Data presented per episodes in the upper part of the table and per samples in the lower part. Percentages are calculated based on the total (positive and
negative) number of episodes or samples respectively.
1Includes one episode with a co-infection by H. influenzae and M. catarrhalis.
2Includes one episode with a bilateral infection, from which the two collected samples were culture positive for S. pneumoniae (unknown serotype, same
susceptibility to antibiotics).
3Includes one episode with a co-infection by S. pneumoniae and H. influenzae.
4Two samples were collected from the 6 children presenting with a bilateral infections, leading to a total of 118 samples from the 112 episodes. No bacteria were
identified in 5 bilateral infections, the last one was positive for S. pneumoniae (27 samples from 26 episodes).
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(4/13) versus 0% and 13% (1/8), respectively). Seventy-
seven percent (10/13) of Hib-positive and 50% (4/8) of
other H-influenzae-positive children had an OS-8 scale
score of greater than 5.
Antibiotic susceptibility
Among the 27 S. pneumoniae isolates, all were susceptible
to amoxicillin/clavulanate and to penicillin, 11% (3/27)
were non-susceptible to cefotaxime, 63% (17/27) were
non-susceptible to cefuroxime, 67% (18/27) were non-
susceptible to erythromycin and 78% (21/27) were non-
susceptible to trimethoprim/sulfamethoxazole (Table 3).
Eighty-one percent (22/27) of S. pneumoniae isolates were
multidrug resistant. Among 19F isolates, the most promin-
ent serotype, 2 out of 7 were non-susceptible to cefotax-
ime and 5 out of 7 were non-susceptible to cefuroxime. All
H. influenzae isolates were susceptible to amoxicillin/
clavulanate and to cefotaxime, 5% (1/21) was non-susceptible
to cefuroxime, and 20% (4/20) were non-susceptible to
ampicillin, with ampicillin data missing for one isolate
(Table 3). Three of the 4 isolates not susceptible to ampi-
cillin were Hib isolates. One (Hib) of the 21H. influenzae
isolates was beta-lactamase-negative ampicillin-resistant
but susceptible to amoxicillin/clavulanate.
Discussion
The AOM episodes seen in this study among children
who sought care from ENTs in Thailand were generally
non-recurrent episodes assessed by tympanocentesis. Inthis study environment, where there was minimal use of
either Hib or pneumococcal vaccine, bacterial pathogens
were an important cause of AOM. The leading causes of
bacterial AOM were S. pneumoniae and H. influenzae,
representing 47% (27/57) and 37% (21/57) of culture-
positive samples, respectively. The majority of H. influen-
zae was serotype b (62% (13/21)). Forty-eight percent of
samples were culture-positive for one of the pathogens
under study, slightly lower than the 53-58% reported in
other settings [24], but consistent with the assumption
that isolation of bacteria may be lower in an environment
with high antibiotic use [25]. Other studies have found
that PCR can detect bacteria in culture-negative MEF
[26], so it is possible that these pathogens play a greater
role in AOM than what was detected here.
We found slightly more S. pneumoniae than H. influen-
zae, consistent with what was seen elsewhere in the pre-
PCV7 era [3]. In this population, AOM episodes were
generally comprised of relatively mild, sporadic cases, ra-
ther than severe or recurrent. H. influenzae was slightly
more prominent than S. pneumoniae in children 12–23
months of age while the reverse was true in children
24–59 months of age. Overall, the symptom profiles and
potential risk factor profiles of S. pneumoniae and
H. influenzae were generally similar.
One unexpected finding in the studywas the higher
than expected presence of Hib. This was a surprise in
part because available data suggest a low incidence of
Hib-associated invasive disease in Thailand [27], al-
though there are concerns that existing data from Asia
Figure 2 Culture results and pathogens under study identified from middle ear fluid samples (N = 118). Culture results from middle ear
fluid samples including serotype distribution for S. pneumoniae (Spn, n = 27), and H. influenzae (H. inf, n = 21). There were two co-infected samples
due to one co-infection of S. pneumoniae 23F and H. influenzae serotype a, and one co-infection of Hib and M. catarrhalis.
Table 2 Symptoms reported at the visit for AOM patients in the study
S. pneumoniae positive (N = 26) Non-Hib H. influenzae positive (N = 8) Hib positive (N = 13) Total (N = 112)
Ear pain 25 (96%) 8 (100%) 13 (100%) 106 (95%)
OS-8 > 5 15 (58%) 4 (50%) 10 (77%) 64 (57%)
Irritability 16 (62%) 0 (0%) 7 (54%) 55 (49%)
Tugging 6 (23%) 1 (13%) 4 (31%) 33 (29%)
Temperature – axillary
37.5-39.0°C 12 (46%) 2 (25%) 3 (23%) 30 (27%)
> 39.0°C 3 (12%) 0 (0%) 0 (0%) 6 (5%)
Trouble sleeping 2 (8%) 2 (25%) 4 (31%) 28 (25%)
Anorexia 4 (15%) 0 (0%) 1 (8%) 16 (14%)
Vomiting 3 (12%) 0 (0%) 1 (8%) 10 (9%)
Diarrhea 0 (0%) 0 (0%) 1 (8%) 4 (4%)
Hearing loss 1 (4%) 0 (0%) 2 (15%) 3 (3%)
Conjunctivitis 0 (0%) 0 (0%) 0 (0%) 2 (2%)
Lethargy 2 (8%) 0 (0%) 0 (0%) 2 (2%)
N = number of episodes, data presented as n (%).
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Table 3 Antibacterial non-susceptibility of S. pneumoniae and H. influenzae isolates
Number of non-susceptible1 isolates
Antibiotic S. pneumoniae isolates (N = 27)2 H. influenzae isolates (N = 21)
Amoxicillin/Clavulanate 0 (0%) 0 (0%)
Ampicillin3 - 4 (20%)
Azithromycin 26 (96%) 2 (10%)
Cefotaxime 3 (11%) 0 (0%)
Cefuroxime 17 (63%) 1 (5%)
Chloramphenicol 7 (26%) 2 (10%)
Erythromycin4 18 (67%) -
Levofloxacin 0 (0%) 0 (0%)
Penicillin4 0 (0%) -
Tetracycline 18 (67%) 2 (10%)
Trimethoprim/Sulfamethoxazole 21 (78%) 7 (33%)
1Intermediate or resistant based on the Clinical and Laboratory Standards Institute 2009 standards.
2Two isolates are coming from the same child with a bilateral infection.
3Ampicillin resistance data missing for one H. influenzae isolate. Ampicillin sensitivity was not performed for S. pneumoniae.
4For H. influenzae, the median value of MIC was equal to 4.0 for Erythromycin and 0.250 for Penicillin.
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a global level, Hib is generally perceived not to be an im-
portant AOM pathogen. Before the introduction of the
Hib vaccine in the United States, for example, Hib only
represented 10% of H. influenzae AOM cases [30], while
in our study, Hib was seen in 62% of the H. influenzae
isolates. Another exception to the general observation
that encapsulated H. influenzae are not important causes
of AOM comes from a recent, tympanocentesis-based
study in Venezuela where 31% of H. influenzae AOM
were encapsulated a, c, d and f strains (Venezuela has
universal Hib immunization) [31]. Interestingly, based
on the OS-8 scale, the Thai Hib cases seemed to be
slightly more severe than S. pneumoniae or non-Hib H.
influenzae cases.
A second surprising finding was that the median age
of children in the study was 36 months, which is un-
usual given that AOM incidence elsewhere generally
peaks at 6–18 months of age. Since the age of the
screened cohort was only slightly younger than the en-
rolled cohort it does not appear that there was signifi-
cant bias in the final study sample (i.e., those who
received tympanocentesis) compared to all children who
came to the ENT with suspected AOM. While it is pos-
sible that the true burden of AOM in Thailand tends to
be in older children, it also may be that younger children
with AOM are more often treated at home or by general
practitioners and do not tend to visit the ENT. We note
that a number of children could not be enrolled because
of otorrhea for greater than 24 hours, which may suggest
more severe AOM or may suggest that access to prompt
care is limited, by distance or other factors.
The distribution of S. pneumoniae serotypes was simi-
lar to what has been reported in the literature [10,32]prior to PCV introduction. The generally mild profile
of AOM experienced by the children in our study may
explain the slightly higher than expected proportion of
M. catarrhalis isolates, as this pathogen is often associ-
ated with milder disease [33].
Due to the risk of treatment failures, up-to-date infor-
mation on antibiotic resistance has important clinical
implications for determining the best approach for treat-
ment of AOM [19]. Our results show high levels of re-
sistance of S. pneumoniae to some antibiotics commonly
given in Thailand for respiratory infections (Azithromy-
cin, Cefuroxime, Erythromycin, Tetracycline, Trimetho-
prim/Sulfamethoxazole), and a high level of multidrug
resistance. This was consistent with results from another
study in Asian countries [34], which also noted a high
level of resistance to macrolides. In our study only a low
rate of cefotaxime non-susceptibility was seen, likely due
to the fact that cephalosporins are generally only pre-
scribed for children presenting with severe illness (moder-
ate to severe otalgia or fever of 39°C ) at first visit or for
patients who do not respond to initial treatment. Anti-
biotic resistance was less common for H. influenzae, and
was similar to previously published estimates, though our
isolates had lower levels of resistance to chloramphenicol
(10% versus 25%) and ampicillin (15% versus 48%) [35]. It
is possible that more severe AOM cases than were seen in
this study would be enriched for more resistant AOM.
Currently Hib vaccine use in Thailand is extremely lim-
ited as it is not on the Expanded Program of Immunization
for Thailand [35]. Uptake of PCV7 in Thailand, which
is mainly used in private settings, has also been low
[10], and there were no reports of pneumococcal vaccine
use in the children in our study. Two other pneumococcal
vaccines, Prevenar/Prevnar 13™ (Wyeth, LLC) (PCV13)
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have been licensed in recent years, and differ from PCV7
in the inclusion of 6 (1, 3, 5, 6A, 7F, 19A) and 3 (1, 5, 7F)
additional serotypes, respectively. PHiD-CV also utilizes
as the predominant carrier protein an outer membrane
protein (protein D) derived from H. influenzae, as a pro-
tein D-containing 11-valent precursor formulation of
PHiD-CV was previously shown to be efficacious against
both pneumococcal and H. influenzae AOM [36]. Efficacy
of PHiD-CV itself against AOM was also recently demon-
strated in another double-blind randomized clinical study
[37]. Although PCV13 efficacy against AOM has not yet
been assessed, such data do exist for its predecessor for-
mulation PCV7 [38]. Of the 22 pneumococcal isolates
whose serotype could be identified, at least 16 (73%) rep-
resent a serotype contained in each of the two higher
valent vaccines. Serotype 3, contained only in PCV13, was
also identified in 4/22 (18%) of those pneumococcal iso-
lates, but it remains unclear whether serotype 3 disease is
vaccine-preventable [39]. Our results thus suggest that ei-
ther vaccine would likely prevent a significant proportion
of AOM cases.
The study was successful in adding to the limited data
on AOM in Thailand, but there are important limita-
tions, including few cases in the youngest children, small
sample size and lack of a clear population denominator.
The study did cover several, but not all, regions of
Thailand, and therefore is somewhat limited in geograph-
ical representativeness. As the use of a Hib vaccine is
known to be very limited in Thailand, we did not collect
individual Hib vaccination status, though it could have
provided further insight into the previously unrecognized
burden of Hib in AOM cases that was identified in this
study. An additional limitation is that the over-the-
counter availability of antibiotics in Thailand could mean
that some children may have received antibiotics before
the study visit, This could have decreased the proportion
of culture positives, and meant that bacteria that were iso-
lated from such patients may have been those with greater
non-susceptibility. However, as it was impossible to know
whether any antibiotics received in this manner were ap-
propriate for AOM and/or provided in sufficient dosage,
only patients receiving antibiotics prescribed by a phys-
ician 48–72 hours prior to the study visit were considered
treatment failures, as per protocol.
Conclusions
In summary, this assessment of AOM etiology in Thai
children 3 to 59 months of age visiting ENT clinics
for AOM showed an unexpectedly high burden of Hib.
S. pneumoniae and H. influenzae were the leading causes
of AOM across all age groups, similar to what has been
seen in Europe, the United States, and Latin America, and
with pneumococcal serotypes similar to those foundelsewhere [32,40]. These findings contribute to the scarce
tympanocentesis literature in this region, and suggest that
conjugate vaccines effective against pneumococcus and
H. influenzae, both encapsulated (Hib) and unencapsu-
lated, may be important in attempts to reduce bacterial
AOM in the region.
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